A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pharmacia and Upjohn
• Treatments: Delavirdine; Indinavir; Zidovudine

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV-positive.

• Have a viral load (level of HIV in the blood) of at least 20,000 copies/ml.

• Have a CD4 cell count of at least 50 cells/mm3.

• Are at least 14 years old (consent of parent or guardian is required if under 18).

Exclusion Criteria

You will not be eligible for this study if you:

• Have ever taken an anti-HIV drug other than ZDV.

• Have taken ZDV for more than 1 month.